“Returning to the NASDAQ Stock Market has been a primary goal for us this year,” said Michael L. Krall, President and Chief Executive Officer of PURE Bioscience. “We expect NASDAQ’s electronic multiple market maker structure to provide our company with enhanced exposure and liquidity, and afford our investors the best prices, the fastest execution, and the lowest cost per trade. As the world’s largest electronic stock market, NASDAQ promotes innovation and attracts leading growth companies from a diverse group of sectors. PURE Bioscience certainly fits that description, and we look forward to being a part of The NASDAQ Stock Market.”
"We are thrilled that PURE Bioscience has chosen to relist their stock on NASDAQ," said Bob McCooey, Senior Vice President of New Listings and Capital Markets of The NASDAQ OMX Group, Inc. "PURE Bioscience joins the world’s largest exchange company that spans six continents.” We look forward to supporting PURE Bioscience and its shareholders as they make their transition to NASDAQ."
About PURE Bioscience
PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com
